{"id":"aon-d21","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL5762161","moleculeType":null,"molecularWeight":"473.49"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AON-D21 works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to a decrease in the activity of AKT and mTOR, resulting in anti-tumor effects.","oneSentence":"AON-D21 is a small molecule that targets the PI3K/AKT/mTOR pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:33.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT05962606","phase":"PHASE2","title":"Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.","status":"COMPLETED","sponsor":"Aptarion Biotech AG","startDate":"2024-02-02","conditions":"Community-acquired Pneumonia","enrollment":150},{"nctId":"NCT05343819","phase":"PHASE1","title":"Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects.","status":"COMPLETED","sponsor":"Aptarion Biotech AG","startDate":"2022-04-12","conditions":"Healthy","enrollment":16},{"nctId":"NCT05018403","phase":"PHASE1","title":"First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Aptarion Biotech AG","startDate":"2021-08-03","conditions":"Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AON-D21","genericName":"AON-D21","companyName":"Aptarion Biotech AG","companyId":"aptarion-biotech-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AON-D21 is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}